A. Zappi

Lurbinectedin in the therapeutic landscape of SCLC: key clinical evidence and evolving role in the era of emerging therapies.

Despite recent therapeutic advances, durable disease control in small cell lung cancer (SCLC) remains challenging, particularly after relapse following platinum-based chemo-immunotherapy. Lurbinectedin, a selective inhibitor of oncogenic transcription, has emerged as a novel therapeutic agent with a distinct mechanism...